Testing a pill and gel for vitiligo
Part of Skin clinical trials.
This trial tests two forms of a drug (SHR0302) for non-segmental vitiligo. One is a pill, the other a gel. The goal is to see if they can repigment the skin with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between ages 18 and 75.
- Have been diagnosed with non-segmental vitiligo (the common type).
- Agree to stop all other vitiligo treatments and medicated creams during the study.
- Not be pregnant, planning to become pregnant, or nursing.
- Have no active skin infections or other skin conditions that could interfere.
- No history of tuberculosis, HIV, hepatitis B/C, or other serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medication (ACT-777991) taken by mouth to see if it can help repigment skin in adults with non-segmental vitiligo. It aims to learn how safe it is and how well it works.
This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.
This trial tests an investigational drug called ICP-332 for vitiligo that isn't limited to one area (non-segmental). It aims to see if the drug can help restore skin color. The study is for both adults and teenagers who have had vitiligo for at least 3 months with a certain amount of skin affected.
This study tests a new drug called EI-001 for people with non-segmental vitiligo (a type where white patches appear on both sides of the body). It is for those whose vitiligo has not gotten better with standard treatments like creams or light therapy, or who cannot use those treatments.
This trial tests an oral tablet called VC005 to see if it can help treat non-segmental vitiligo. It may be an option for adults with vitiligo patches that are not limited to one area of the body.
This study tests a new medication called FXS5626 to help treat non-segmental vitiligo (a type of vitiligo that affects both sides of the body). It is for people who have moderate to large patches of vitiligo, especially on the face.
Hear when a new Non-segmental Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.